Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALT Altimmune	$3.50 -3.0%	$5.75	$2.90 ▼ $11.16	$283.89M	0.58	3.18 million shs	19.92 million shs
ELUT Elutia	$2.10 +13.5%	$1.91	$1.61 ▼ $5.24	$86.35M	0.86	43,951 shs	43,150 shs
MREO Mereo BioPharma Group	$2.66 -5.0%	$2.51	$1.58 ▼ $5.02	$422.94M	0.48	1.09 million shs	1.06 million shs
ZVRA Zevra Therapeutics	$9.00 -3.0%	$8.41	$4.20 ▼ $9.76	$492.12M	2.01	675,798 shs	1.45 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALT Altimmune	0.00%	-50.34%	-35.54%	-30.00%	-47.37%
ELUT Elutia	0.00%	+16.02%	+16.67%	-17.00%	-57.66%
MREO Mereo BioPharma Group	0.00%	-6.67%	+24.30%	+18.22%	-26.11%
ZVRA Zevra Therapeutics	0.00%	-0.44%	+5.63%	+20.16%	+83.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALT Altimmune	2.2612 of 5 stars	3.5	1.0	2.9	1.7	0.6
ELUT Elutia	3.8709 of 5 stars	3.5	5.0	3.4	3.3	0.6
MREO Mereo BioPharma Group	2.52 of 5 stars	3.6	3.0	2.7	1.7	0.0
ZVRA Zevra Therapeutics	2.3736 of 5 stars	3.6	3.0	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALT Altimmune	3.00	Buy	$19.00	442.86% Upside
ELUT Elutia	3.00	Buy	$8.00	280.95% Upside
MREO Mereo BioPharma Group	3.20	Buy	$7.60	185.71% Upside
ZVRA Zevra Therapeutics	3.11	Buy	$22.29	147.62% Upside

Current Analyst Ratings Breakdown

Latest ELUT, ZVRA, MREO, and ALT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	ALT Altimmune	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
6/27/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00
5/14/2025	ZVRA Zevra Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
5/14/2025	ZVRA Zevra Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00 ➝ $25.00
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
5/9/2025	ELUT Elutia	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
4/9/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/3/2025	ALT Altimmune	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALT Altimmune	$20K	14,194.25	N/A	N/A	$1.74 per share	2.01
ELUT Elutia	$24.38M	3.54	N/A	N/A	($1.31) per share	-1.60
MREO Mereo BioPharma Group	$10M	42.29	N/A	N/A	$0.39 per share	6.82
ZVRA Zevra Therapeutics	$23.61M	20.84	N/A	N/A	$0.74 per share	12.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALT Altimmune	-$95.06M	-$1.26	N/A	N/A	N/A	-451,200.00%	-65.44%	-58.43%	8/6/2025 (Estimated)
ELUT Elutia	-$53.95M	-$1.93	N/A	N/A	N/A	-168.23%	N/A	-96.70%	7/28/2025 (Estimated)
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-69.33%	-57.27%	8/12/2025 (Estimated)
ZVRA Zevra Therapeutics	-$105.51M	-$1.90	N/A	45.00	N/A	-226.78%	-201.05%	-53.55%	8/12/2025 (Estimated)

Latest ELUT, ZVRA, MREO, and ALT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	ALT Altimmune	-$0.35	-$0.26	+$0.09	-$0.26	$0.00 million	$0.01 million
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/13/2025	Q1 2025	ZVRA Zevra Therapeutics	-$0.21	-$0.06	+$0.15	-$0.06	$16.96 million	$20.40 million
5/8/2025	Q1 2025	ELUT Elutia	-$0.20	-$0.21	-$0.01	-$0.21	$6.65 million	$6.03 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALT Altimmune	N/A	N/A	N/A	N/A	N/A
ELUT Elutia	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALT Altimmune	N/A	15.85	15.85
ELUT Elutia	N/A	0.81	0.70
MREO Mereo BioPharma Group	N/A	8.92	8.92
ZVRA Zevra Therapeutics	1.46	3.02	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALT Altimmune	78.05%
ELUT Elutia	74.03%
MREO Mereo BioPharma Group	62.83%
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ALT Altimmune	4.10%
ELUT Elutia	27.60%
MREO Mereo BioPharma Group	5.50%
ZVRA Zevra Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALT Altimmune	50	81.11 million	77.78 million	Optionable
ELUT Elutia	180	41.12 million	29.77 million	Not Optionable
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
ZVRA Zevra Therapeutics	20	54.68 million	53.37 million	Optionable

ELUT, ZVRA, MREO, and ALT Headlines

Recent News About These Companies

Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $22.29

June 23, 2025 | americanbankingnews.com

Carret Asset Management LLC Buys Shares of 36,140 Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 21, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Analysts

June 20, 2025 | marketbeat.com

Cantor Fitzgerald Predicts ZVRA FY2026 Earnings

June 11, 2025 | marketbeat.com

Bank of America Corp DE Increases Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 9, 2025 | marketbeat.com

Nuveen Asset Management LLC Reduces Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

June 5, 2025 | marketbeat.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Purchased by Millennium Management LLC

June 3, 2025 | marketbeat.com

Zevra Therapeutics: Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 31, 2025 | finanznachrichten.de

Zevra Therapeutics Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to Board of Directors Amid Commitment to Growth Strategy

May 31, 2025 | nasdaq.com

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 29, 2025 | globenewswire.com

Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT

May 27, 2025 | insidermonkey.com

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 21, 2025 | globenewswire.com

Analysts Offer Insights on Healthcare Companies: Flora Growth (FLGC), Cardinal Health (CAH) and Zevra Therapeutics (ZVRA)

May 16, 2025 | theglobeandmail.com

With 49% stake, Zevra Therapeutics, Inc. (NASDAQ:ZVRA) seems to have captured institutional investors' interest

May 15, 2025 | finance.yahoo.com

Zevra Reports First Quarter 2025 Financial Results and Corporate Update

May 13, 2025 | taiwannews.com.twT

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 13, 2025 | seekingalpha.com

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Zevra Therapeutics, Inc. Q1 2025 Earnings Preview

May 12, 2025 | msn.com

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

May 6, 2025 | globenewswire.com

Zevra Therapeutics to Participate in the Citizens Life Science Conference

May 1, 2025 | finance.yahoo.com

Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders

April 21, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT, ZVRA, MREO, and ALT Company Descriptions

Altimmune NASDAQ:ALT

$3.50 -0.11 (-3.05%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.47 -0.03 (-0.83%)

As of 06/27/2025 08:00 PM Eastern

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Elutia NASDAQ:ELUT

$2.10 +0.25 (+13.51%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.04 -0.06 (-2.62%)

As of 06/27/2025 07:33 PM Eastern

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Mereo BioPharma Group NASDAQ:MREO

$2.66 -0.14 (-5.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.71 +0.05 (+1.88%)

As of 06/27/2025 06:36 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Zevra Therapeutics NASDAQ:ZVRA

$9.00 -0.28 (-3.02%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$8.99 -0.01 (-0.06%)

As of 06/27/2025 04:34 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time